Alterations of SMARCD1, SMARCD2 or SMARCD3 were each found in 6% of a patient cohort suffering from non-metastatic PCa of various clinical stages (n = 488; T2a-T4) (Figure 1A). This evidence concerns the gene SMARCD2 and posterior cortical atrophy.